Labiotech.eu

News and Trends 20 Jan 2015

Will Microalgaes solve the Rare Earth conflict?

The extraction of rare earths is a very expensive process, having dramatic consequences for the planet (degradation, impacts on water quality, etc.). Currently, China controls 95% of the World production of these minerals widely used in the field of new technologies and electronics. The development of new methods of sustainable recycling from waste and environmentally friendly is […]

January 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 17 Jan 2015

Qiagen, the new giant in next-gen sequencing tools?

Yet again, a new acquisition in this beginning of 2015. Enzymatics, the Boston-area based Biotech company and leading provider of enzymes for Next-gen sequencing, has been acquired by Qiagen for a non-disclosed amount. The amount must be pretty high since Enzymatics’ enzymes are used in 80% of all NGS reactions and the company counts over 150 employees. […]

January 17, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Jan 2015

Roche spent $1B for the Leading Molecular Information Biotech company: Foundation Medicine

2015 starts in a rush for the Biotech industry. Swiss Pharma-giant Roche just announced paying $1B to acquire 56% percent of leading molecular information and genomic analysis Biotech company Foundation Medicine. Foundation Medicine is a leading Biotech company in the field of molecular information and genomic analysis. It uses next-gen sequencing technology and solid bioinformatic analysis […]

January 13, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 9 Jan 2015

Will Nestlé lead the promising microbiome industry?

Nestlé is one of the food giants in the World. Last Tuesday, it made a huge step in the microbiome industry by investing $65M in Boston-based Seres Health, one of the most advanced Biotech start-ups in the field. Will Nestlé take control of the promising microbiome industry? Seres Health is a leading microbiome therapeutics platform company developing […]

January 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 8 Jan 2015

Nanobiotix on its way to change the paradigm in cancer therapy

Nanobiotix is an oncology focused nanomedicine company developing an innovative nanoparticle technology. Their NanoXray technology comprises three products having the potential to cause a paradigm shift in cancer therapy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. The following video is showing how this disruptive technology is acting […]

January 8, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 6 Jan 2015

The largest VC investment in a single Biotech company has just been made

Wow, 2015 starts in a rush for the biotech industry. Moderna Therapeutics, Boston-based company led by French co-founding CEO Stephan Bancel just raised $450M (€380M) in VC investment. According to The Wall Street Journal, it is the largest VC-Investment ever made in a Biotech company. Moderna was founded only in 2011 and is an awesome company […]

January 6, 2015 - 1 minutemin - By Philip Hemme

News and Trends 22 Dec 2014

Biotech’s crowdfunding: is France top of the class?

No need to present the crowdfunding again! We hear about it every day through Kickstarter’s projects or other platforms that abound on the web. But what about biotech’s crowdfunding? Through many French entrepreneur’s interviews who are engaged in crowdfunding’s campaigns, I tried to make my own idea about this new financing tool. And one thing […]

December 22, 2014 - 5 minutesmins - By Joachim Eeckhout

News and Trends 20 Dec 2014

French Biotech Start-up Adocia signs Massive €464M Diabetes Deal with Eli Lilly

The French biotechnology company Adocia entered into an alliance with the US Eli Lilly on the co-development of an ultra-fast insulin to treat type 1 and type 2 diabetes. This insuline, called BioChaperone Lispro, has been developed through Adocia’s technology BioChaperone, is currently in Phase Ib clinical study. Under this global license agreement with Adocia, Eli Lilly […]

December 20, 2014 - 2 minutesmins - By Philip Hemme

News and Trends 19 Dec 2014

The French Leader in Insect Transformation Raised 5,5 Million Euros

Nine months after its first 1.8 million euros funding campaign, YNSECT, “The Insect Company”, a company specialized in insect biotechnology, has raised another 5.5 million euros. YNSECT is on its way to become a European and World leader in the insect field. The world is facing a major challenge: the food demand is expected to double by […]

December 19, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 16 Dec 2014

An Effective Renewed Partnership for Treatment of Gynecological Cancers

Curie-Cancer, the part responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, extended their partnership to develop the 3C23K antibody for the treatment of gynecological cancers. An initial partnership agreement was concluded in 2013 and the results of work on the 3C23K antibody were presented to the Ovarian […]

December 16, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 15 Dec 2014

Will there be a New Merck-Serono?

GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought an option for €38M on the marketing rights outside the United States and Japan for a treatment against multiple sclerosis. Could GeNeuro become the next Merck-Serono? This amount will allow the Swiss company to continue the clinical development of this molecule. […]

December 15, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 11 Dec 2014

After Merck’s Big Deal, Pfizer Collaborates with iTeos Therapeutics for Cancer Treatments

iTeos Therapeutics SA enters in a strategic collaboration with Pfizer Inc where iTeos will license to Pfizer rights to iTeos’ pre-clinical compounds targeting the enzymes expressed in many cancers. Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. It completes a previous deal with Merck a few weeks ago. Additionally, […]

December 11, 2014 - 2 minutesmins - By Julie Lellouche

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Will Microalgaes solve the Rare Earth conflict?

Qiagen, the new giant in next-gen sequencing tools?

Roche spent $1B for the Leading Molecular Information Biotech company: Foundation Medicine

Will Nestlé lead the promising microbiome industry?

Nanobiotix on its way to change the paradigm in cancer therapy

The largest VC investment in a single Biotech company has just been made

Biotech’s crowdfunding: is France top of the class?

French Biotech Start-up Adocia signs Massive €464M Diabetes Deal with Eli Lilly

The French Leader in Insect Transformation Raised 5,5 Million Euros

An Effective Renewed Partnership for Treatment of Gynecological Cancers

Will there be a New Merck-Serono?

After Merck’s Big Deal, Pfizer Collaborates with iTeos Therapeutics for Cancer Treatments

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!